Published in Naunyn Schmiedebergs Arch Pharmacol on November 10, 2013
ADME studies and preliminary safety pharmacology of LDT5, a lead compound for the treatment of benign prostatic hyperplasia. Braz J Med Biol Res (2016) 0.75
Protein measurement with the Folin phenol reagent. J Biol Chem (1951) 1743.91
Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods (1983) 114.35
Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol (1973) 47.81
How many drug targets are there? Nat Rev Drug Discov (2006) 14.22
A review of central 5-HT receptors and their function. Neuropharmacology (1999) 6.13
New uses for old drugs. Nature (2007) 5.86
Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol (2011) 5.01
EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol (2013) 4.89
Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov (2004) 4.31
The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol Sci (2005) 3.02
Two functionally distinct alpha2-adrenergic receptors regulate sympathetic neurotransmission. Nature (1999) 2.55
Subclassification of alpha 1-adrenoceptor recognition sites by urapidil derivatives and other selective antagonists. Br J Pharmacol (1989) 2.00
Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol (2006) 1.83
Privileged structures: applications in drug discovery. Comb Chem High Throughput Screen (2004) 1.82
BMY 7378 is a selective antagonist of the D subtype of alpha 1-adrenoceptors. Eur J Pharmacol (1995) 1.61
Characterization of an alpha 1D-adrenoceptor mediating the contractile response of rat aorta to noradrenaline. Br J Pharmacol (1995) 1.57
Alpha 1-adrenergic receptor regulation: basic science and clinical implications. Pharmacol Ther (2000) 1.42
Correlation between benign prostatic hyperplasia and inflammation. Curr Opin Urol (2013) 1.34
Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. Cancer Res (2000) 1.29
Multi-target drugs: the trend of drug research and development. PLoS One (2012) 1.28
Is alpha1D-adrenoceptor protein detectable in rat tissues? Naunyn Schmiedebergs Arch Pharmacol (1997) 1.11
Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines. Prostate (2004) 1.08
Quantification and distribution of alpha 1-adrenoceptor subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and non-hypertrophied tissue. Br J Pharmacol (1996) 1.05
The effects of tamsulosin, a high affinity antagonist at functional alpha 1A- and alpha 1D-adrenoceptor subtypes. Br J Pharmacol (1997) 1.03
Radioligand binding studies of alpha 1-adrenoceptor subtypes in rat heart. Br J Pharmacol (1994) 1.02
The role of serotonin (5-hydroxytryptamine1A and 1B) receptors in prostate cancer cell proliferation. J Urol (2006) 1.00
Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: mechanistic significance of the quinazoline component. Prostate Cancer Prostatic Dis (2002) 0.99
Structure activity relationships of a series of buspirone analogs at alpha-1 adrenoceptors: further evidence that rat aorta alpha-1 adrenoceptors are of the alpha-1D-subtype. J Pharmacol Exp Ther (1996) 0.97
The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: alpha-blockers in the treatment of male voiding dysfunction - how do they work and why do they differ in tolerability? J Pharmacol Sci (2010) 0.97
Alpha 1-adrenoceptors: subtypes, signaling, and roles in health and disease. Arch Med Res (2000) 0.94
Quantification of alpha1-adrenoceptor subtypes by real-time RT-PCR and correlation with age and prostate volume in benign prostatic hyperplasia patients. Prostate (2006) 0.91
Intrinsic activity determinations at the dopamine D2 guanine nucleotide-binding protein-coupled receptor: utilization of receptor state binding affinities. Mol Pharmacol (1992) 0.90
Serotonin activates MAP kinase and PI3K/Akt signaling pathways in prostate cancer cell lines. Urol Oncol (2009) 0.89
Prostate growth inhibition by subtype-selective alpha(1)-adrenoceptor antagonist naftopidil in benign prostatic hyperplasia. Prostate (2009) 0.88
A signaling network in phenylephrine-induced benign prostatic hyperplasia. Endocrinology (2009) 0.88
Correlation between low/high affinity ratios for 5-HT(1A) receptors and intrinsic activity. Eur J Pharmacol (1999) 0.87
BPH: costs and treatment outcomes. Am J Manag Care (2006) 0.84
The alpha 1d-adrenoceptor subtype is involved in the noradrenaline-induced contractions of rat aorta. Life Sci (1995) 0.83
Cyclic GMP-dependent vasodilatory properties of LASSBio 294 in rat aorta. Br J Pharmacol (2002) 0.82
5-HT1A receptor pharmacophores to screen for off-target activity of α1-adrenoceptor antagonists. J Comput Aided Mol Des (2013) 0.82
5-HT activates ERK MAP kinase in cultured-human peripheral blood mononuclear cells via 5-HT1A receptors. Life Sci (2004) 0.80
Pharmacological profile of the novel alpha-adrenoceptor antagonist KT-611 (naftopidil). Jpn J Pharmacol (1991) 0.79
In vivo involvement of endothelium-derived nitric oxide in spontaneously hypertensive rats: effects of NG-nitro-L-arginine methyl ester. J Hypertens Suppl (1991) 0.79
Animal models for benign prostatic hyperplasia. Handb Exp Pharmacol (2011) 0.78
Discovery of LASSBio-772, a 1,3-benzodioxole N-phenylpiperazine derivative with potent alpha 1A/D-adrenergic receptor blocking properties. Eur J Med Chem (2011) 0.78
Differential antagonism by conotoxin rho-TIA of contractions mediated by distinct alpha1-adrenoceptor subtypes in rat vas deferens, spleen and aorta. Eur J Pharmacol (2005) 0.78
Searching for multi-target antipsychotics: Discovery of orally active heterocyclic N-phenylpiperazine ligands of D2-like and 5-HT1A receptors. Bioorg Med Chem (2010) 0.78
5-HT1A-agonistic properties of naftopidil, a novel antihypertensive drug. Eur J Pharmacol (1991) 0.77
A two model receptor system of the alpha1D adrenergic receptor to describe interactions with epinephrine and BMY7378. J Chem Inf Model (2006) 0.77
5-HT1A receptor agonist properties of antipsychotics determined by [35S]GTPgammaS binding in rat hippocampal membranes. Clin Exp Pharmacol Physiol (2007) 0.76
Multi-target strategy to address Alzheimer's disease: design, synthesis and biological evaluation of new tacrine-based dimers. Eur J Med Chem (2011) 0.76
[3H]Pirenzepine and [3H]quinuclidinyl benzilate binding to brain muscarinic cholinergic receptors. Differences in measured receptor density are not explained by differences in receptor isomerization. Mol Pharmacol (1984) 0.76
Design, synthesis and biological evaluation of pyridine-phenylpiperazines: a novel series of potent and selective alpha1a-adrenergic receptor antagonist. Bioorg Med Chem (2000) 0.75
Structure-activity relationship studies of CNS agents, Part 32: Effect of structural modifications in 1-arylpiperazine derivatives on alpha(1) -adrenoreceptor affinity. Arch Pharm (Weinheim) (1997) 0.75
Structure-activity relationship studies of CNS agents, XIX: Quantitative analysis of the alkyl chain effects on the 5-HT1A and 5-HT2 receptor affinities of 4-alkyl-1-arylpiperazines and their analogs. Arch Pharm (Weinheim) (1995) 0.75
WITHDRAWN: Terazosin for benign prostatic hyperplasia. Cochrane Database Syst Rev (2011) 0.75
Natriuretic effect of bufalin in isolated rat kidneys involves activation of the Na+-K+-ATPase-Src kinase pathway. Am J Physiol Renal Physiol (2012) 1.50
Identification and characterization of coumestans as novel HCV NS5B polymerase inhibitors. Nucleic Acids Res (2008) 1.04
Structure-activity relationship of wedelolactone analogues: structural requirements for inhibition of Na+, K+ -ATPase and binding to the central benzodiazepine receptor. Bioorg Med Chem (2006) 0.86
Insights into the mechanism of erythrocyte Na+/K+-ATPase inhibition by nitric oxide and peroxynitrite anion. J Appl Toxicol (2003) 0.84
Adaptive expression pattern of different proteins involved in cellular calcium homeostasis in denervated rat vas deferens. Eur J Pharmacol (2005) 0.83
Multiple level C in vitro/in vivo correlation of dissolution profiles of two L-thyroxine tablets with pharmacokinetics data obtained from patients treated for hypothyroidism. Eur J Pharm Sci (2004) 0.83
Ivermectin is a nonselective inhibitor of mammalian P-type ATPases. Naunyn Schmiedebergs Arch Pharmacol (2009) 0.82
Flavones and phenylpropanoids from a sedative extract of Lantana trifolia L. Phytochemistry (2009) 0.81
Stereoselective synthesis and preliminary evaluation of new D-3-heteroarylcarbonylalanines as ligands of the NMDA receptor. Bioorg Med Chem Lett (2004) 0.81
Increased endothelial cell-leukocyte interaction in murine schistosomiasis: possible priming of endothelial cells by the disease. PLoS One (2011) 0.80
Synthesis and preliminary pharmacological evaluation of new (+/-) 1,4-naphthoquinones structurally related to lapachol. Bioorg Med Chem (2002) 0.80
Synthesis, biological evaluation, and structure-activity relationship of clonazepam, meclonazepam, and 1,4-benzodiazepine compounds with schistosomicidal activity. Chem Biol Drug Des (2012) 0.80
Endothelial P2X7 receptors' expression is reduced by schistosomiasis. Purinergic Signal (2012) 0.79
Characterization of subcellular fractions and distribution profiles of transport components involved in Ca(2+) homeostasis in rat vas deferens. J Pharmacol Toxicol Methods (2002) 0.79
Evidence for the presence of glutamatergic receptors in adult Schistosoma mansoni. Biochem Pharmacol (2002) 0.79
Discovery of LASSBio-772, a 1,3-benzodioxole N-phenylpiperazine derivative with potent alpha 1A/D-adrenergic receptor blocking properties. Eur J Med Chem (2011) 0.78
Searching for multi-target antipsychotics: Discovery of orally active heterocyclic N-phenylpiperazine ligands of D2-like and 5-HT1A receptors. Bioorg Med Chem (2010) 0.78
Characterization of a new synthetic isoflavonoid with inverse agonist activity at the central benzodiazepine receptor. Eur J Pharmacol (2004) 0.78
Influence of development on Na(+)/K(+)-ATPase expression: isoform- and tissue-dependency. Comp Biochem Physiol A Mol Integr Physiol (2002) 0.78
Mechanisms of adaptive supersensitivity in vas deferens. Auton Neurosci (2009) 0.77
Synthesis and pharmacological evaluation of new N-phenylpiperazine derivatives designed as homologues of the antipsychotic lead compound LASSBio-579. Eur J Med Chem (2013) 0.77
Role of noradrenaline on the expression of the Na+/K+-ATPase alpha2 isoform and the contractility of cultured rat vas deferens. Biochem Pharmacol (2002) 0.77
Pharmacokinetic/pharmacodynamic modeling of psychomotor impairment induced by oral clonazepam in healthy volunteers. Ther Drug Monit (2009) 0.77
2-Methoxy-3,8,9-trihydroxy coumestan: a new synthetic inhibitor of Na+,K+-ATPase with an original mechanism of action. Biochem Pharmacol (2003) 0.77
Inhibitory effect of combinations of digoxin and endogenous cardiotonic steroids on Na+/K+-ATPase activity in human kidney membrane preparation. Life Sci (2010) 0.77
Δ²,³-ivermectin ethyl secoester, a conjugated ivermectin derivative with leishmanicidal activity but without inhibitory effect on mammalian P-type ATPases. Naunyn Schmiedebergs Arch Pharmacol (2010) 0.76
Na+/K+-ATPase alpha isoforms expression in stroke-prone spontaneously hypertensive rat heart ventricles: effect of salt loading and lacidipine treatment. Eur J Pharmacol (2007) 0.76
New insights into pharmacological profile of LASSBio-579, a multi-target N-phenylpiperazine derivative active on animal models of schizophrenia. Behav Brain Res (2012) 0.75
The effects of 3-methylclonazepam on Schistosoma mansoni musculature are not mediated by benzodiazepine receptors. Eur J Pharmacol (2009) 0.75
Design of new dopamine D2 receptor ligands: biosynthesis and pharmacological evaluation of the hydroxylated metabolite of LASSBio-581. Bioorg Med Chem Lett (2010) 0.75
In vitro effect of valepotriates isolated from Valeriana glechomifolia on rat P-type ATPases. Planta Med (2011) 0.75
Product listing agreements (PLAs): a new tool for reaching Quebec's pharmaceutical policy objectives? Healthc Policy (2013) 0.75
Schistosomiasis differentially affects vasoconstrictor responses: up-regulation of 5-HT receptor-mediated aorta contraction. Mem Inst Oswaldo Cruz (2011) 0.75
Biotransformation of LASSBio-579 and pharmacological evaluation of p-hydroxylated metabolite a N-phenylpiperazine antipsychotic lead compound. Eur J Med Chem (2012) 0.75
LASSBio-1422: a new molecular scaffold with efficacy in animal models of schizophrenia and disorders of attention and cognition. Behav Pharmacol (2016) 0.75
Mechanisms associated to impaired activity of cardiac P-type ATPases in endothelial nitric oxide synthase knockout mice. J Physiol Biochem (2012) 0.75
Synergistic interaction between ouabain and 8-methoxy-3,9-dihydroxy coumestan, a non-steroidal synthetic inhibitor of Na+,K+-ATPase. Life Sci (2007) 0.75
Binding of [3H]MK-801 in subcellular fractions of Schistosoma mansoni: evidence for interaction with nicotinic receptors. Biochem Pharmacol (2005) 0.75
On-line solid-phase extraction coupled with high-performance liquid chromatography and tandem mass spectrometry (SPE-HPLC-MS-MS) for quantification of bromazepam in human plasma: an automated method for bioequivalence studies. Ther Drug Monit (2005) 0.75
Insights into the mechanism of Na+,K+-ATPase inhibition by 2-methoxy-3,8,9-trihydroxy coumestan. Bioorg Med Chem (2008) 0.75